1799328-86-1

1799328-86-1 structure

Name: ASTX660
Chemical Name: ASTX660
CAS Number: 1799328-86-1
Molecular Formula: C₃₀H₄₂FN₅O₃
Molecular Weight: 539.68
Catalog: Signaling Pathways Apoptosis IAP
Create Date: 2018-04-13 06:04:02
Modify Date: 2025-08-27 10:39:02
ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).

Name	ASTX660

Description	ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
Related Catalog	Signaling Pathways >> Apoptosis >> IAP Research Areas >> Cancer
Target	cIAP, XIAP[1]
In Vitro	ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660[1].
In Vivo	In HCC1806 xenografts in mice, ASTX660 (daily oral treatment) causes moderate tumor growth inhibition but not regression[1].
References	[1]. Tomoko Smyth, et al. Abstract 1287: The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo. Cancer Res 2016;76(14 Suppl).